bpc-157 for back pain Could peptides help low and disc injuries? where to inject bpc-157 for

Discover why were the leader in BPC research and development

subsequent to a 2011 inspection which found a number of the company's products contained prescription and investigational drugs and were misbranded

However, they are more common following booster doses of diptheria, tetanus, and pertussis (DTPa/dTpa)

The FDA issued a warning letter in 2023 regarding companies marketing BPC-157 with therapeutic claims, reinforcing that this peptide lacks the evidence base required for approved drug status [2]

Store lyophilized at -20C for long-term stability

Future Directions While preclinical data are compelling, human trials are needed to validate efficacy and dosing